Skip to content

Study · Animal study (in vivo) · mouse · 1997

14 results

Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice.

Badamchian M, Mora CA, Baumann CA, Paino JE, Goldstein AL

International journal of immunopharmacology1 Feb 1997Cited by 4 (Europe PMC)

PMID9278175 (opens in a new tab)DOI10.1016/s0192-0561(97)00007-6 (opens in a new tab)PepBankPUB-09278175
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice given thymosin alpha1 intraperitoneally, serum thymosin alpha1 rose significantly 2 min after injection and stayed raised for 2 h.

    In plain wordsIn mice, thymosin alpha1 levels in blood rose within 2 minutes of injection and stayed raised for 2 hours.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    average serum concentration
    1.55 microg/ml
    2 min to 2 h

    Source sentences

    Summary
    Using a modified enzymatic immunoassay, our data show a significant increase of T alpha1 in serum 2 min after injection and lasting for 2 h (average: 1.55 +/- 0.27 microg/ml).
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In mice given thymosin alpha1 intraperitoneally, urine thymosin alpha1 was increased at four time points between 20 min and 6 h.

    In plain wordsIn mice, thymosin alpha1 levels in urine were raised from 20 minutes to 6 hours after injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseUrine T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    average urine concentration
    25 microg/ml
    20 min to 6 h

    Source sentences

    Summary
    In urine, at four different time points after injection (20 min, 40 min, 2 h, 6 h), increased concentrations of T alpha1 were found between 24.2 and 25.4 microg/ml (average: 25 +/- 0.47 microg/ml).
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, 8.97% of the 500 microg thymosin alpha1 dose was recovered at the end of the study: 2% in urine, 1.25% in serum and 5.72% in organs.

    In plain wordsIn mice, only a small share of the injected thymosin alpha1 was recovered, mostly in organs.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableRecovery of administered T alpha1
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    total recovery
    8.97%
    end of study
    urine recovery
    2%
    urine
    serum recovery
    1.25%
    serum
    organ recovery
    5.72%
    organs

    Source sentences

    Summary
    Of the 500 microg T alpha1 administered to mice, 8.97% was recovered at the end of the study, of which 2% corresponded to urine, 1.25% to serum (2 ml of serum per mouse), and 5.72% to organs.
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, extrapolation to daily urine volume and total serum volume suggested recovery close to 40% in urine and 2.5% in serum.

    In plain wordsIn mice, estimates suggested close to 40% of the dose appeared in urine and 2.5% remained in serum.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableExtrapolated recovery in urine and serum
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    extrapolated urine recovery
    ≈ 40%
    urine
    extrapolated serum recovery
    2.5%
    serum

    Source sentences

    Summary
    Since the urine/day volume and the serum volume of any Swiss Webster mouse is ca 2 ml, additional extrapolation of the above mentioned values could show percentages of recovery close to 40% for urine and 2.5% for serum.
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, thymus thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in the thymus rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymus T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    thymus concentration
    33.1 microg/g
    40 min
    thymus baseline
    18 microg/g
    baseline

    Source sentences

    Summary
    thymus (33.1 +/- 3.5 microg/g vs 18 microg/g baseline)
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, lung thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in the lungs rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLung T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    lung concentration
    7.7 microg/g
    40 min
    lung baseline
    1.9 microg/g
    baseline

    Source sentences

    Summary
    lungs (7.7 +/- 1.1 microg/g vs 1.9 microg/g baseline)
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  7. 07AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, spleen thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in the spleen rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSpleen T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    spleen concentration
    15.6 microg/g
    40 min
    spleen baseline
    5.6 microg/g
    baseline

    Source sentences

    Summary
    spleen (15.6 +/- 0.7 microg/g vs 5.6 microg/g)
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  8. 08AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, kidney thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in the kidneys rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseKidney T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    kidney concentration
    6.2 microg/g
    40 min
    kidney baseline
    3.9 microg/g
    baseline

    Source sentences

    Summary
    kidneys (6.2 +/- 1.1 microg/g vs 3.9 microg/g)
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  9. 09AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, ovary thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in the ovaries rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOvary T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    ovary concentration
    9.2 microg/g
    40 min
    ovary baseline
    0 microg/g
    baseline

    Source sentences

    Summary
    ovaries (9.2 +/- 1.4 microg/g vs 0 microg/g)
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  10. 10AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, peritoneal fat thymosin alpha1 rose significantly within 40 min of injection compared with baseline.

    In plain wordsIn mice, thymosin alpha1 levels in belly fat rose within 40 minutes of injection compared with before injection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePeritoneal fat T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    peritoneal fat concentration
    4 microg/g
    40 min
    peritoneal fat baseline
    0 microg/g
    baseline

    Source sentences

    Summary
    peritoneal fat (4 +/- 1 microg/g vs 0 microg/g).
    2 context sentences
    Summary · context
    In most of the organs, the wet weight concentrations of T alpha1 increased significantly during the first 40 min after injection in comparison to their baseline wet weight concentrations.
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  11. 11AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, liver thymosin alpha1 did not increase significantly after injection.

    In plain wordsIn mice, thymosin alpha1 levels in the liver did not rise significantly after injection.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLiver T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    liver concentration
    1.7 microg/g
    40 min
    liver baseline
    1.4 microg/g
    baseline

    Source sentences

    Summary
    No significant increases were observed in the liver (1.7 +/- 0.1 microg/g vs 1.4 microg/g)
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  12. 12AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, heart thymosin alpha1 did not increase significantly after injection.

    In plain wordsIn mice, thymosin alpha1 levels in the heart did not rise significantly after injection.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHeart T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Comparator
    Baseline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Measurements

    heart concentration
    0.7 microg/g
    40 min
    heart baseline
    0 microg/g
    baseline

    Source sentences

    Summary
    No significant increases were observed in the liver (1.7 +/- 0.1 microg/g vs 1.4 microg/g) and heart (0.7 +/- 0.5 microg/g vs 0 microg/g).
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  13. 13AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, increased thymosin alpha1 concentrations were not detected in brain tissue after injection.

    In plain wordsIn mice, thymosin alpha1 levels in the brain did not rise after injection.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeBrain T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Increased concentrations of T alpha1 were not detected in the brain and skeletal muscle tissues.
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.
  14. 14AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, increased thymosin alpha1 concentrations were not detected in skeletal muscle after injection.

    In plain wordsIn mice, thymosin alpha1 levels in skeletal muscle did not rise after injection.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSkeletal muscle T alpha1 concentration
    Study

    mousen: not reported in source

    female Swiss-Webster mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    500 microg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Increased concentrations of T alpha1 were not detected in the brain and skeletal muscle tissues.
    1 context sentence
    Summary · context
    In the present study, we have studied some pharmacokinetic properties of T alpha1 by measuring its concentrations in serum, urine and ten major organs of female Swiss-Webster mice following administration of 500 microg T alpha1 intraperitoneally.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.